← Leaderboards
Dai Horiuchi
Northwestern University
$1,645,665
Attributed
$1,645,665
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $343.5K · FY2013–23$500K$375K$250K$125K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,645,665 · 3
By mechanism
R00$732,605 · 1
R01$680,046 · 1
K99$233,014 · 1
Top collaborators
No co-investigators on record.
Most similar at Northwestern University
Same institution · by research overlap
- Adam Williams$10,506,483
- Amy Beth Heimberger$11,078,637
- Serdar E Bulun$27,655,930
- Gary E Schiltz$5,645,620
- Elena Martinelli$12,661,037
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsTumorMammary NeoplasmsProgesterone ReceptorsTranscription FactorTriple-Negative Invasive Breast CarcinomaEstrogen ReceptorsMalignant NeoplasmsOverexpressionPhosphotransferasesReceptorReportingBreast Cancer CellTreatment StrategyCollaborationsEpidermal Growth Factor ReceptorCell DeathMalignant Breast NeoplasmMouse ModelOncogenicCellsPathway InteractionsClinically RelevantTumor Xenograft
Grant awards (7)
Investigating Rational Combination Therapies for Triple-Negative Breast Cancer$336,588
R01 · FY2023 · CA · contact PI
Investigating Rational Combination Therapies for Triple-Negative Breast Cancer$343,458
R01 · FY2022 · CA · contact PI
Exploiting synthetic-lethal interactions to target triple-negative breast cancers$239,353
R00 · FY2017 · CA · contact PI
Exploiting synthetic-lethal interactions to target triple-negative breast cancers$244,252
R00 · FY2016 · CA · contact PI
Exploiting synthetic-lethal interactions to target triple-negative breast cancers$249,000
R00 · FY2015 · CA · contact PI
Exploiting synthetic-lethal interactions to target triple-negative breast cancers$116,507
K99 · FY2014 · CA · contact PI
Exploiting synthetic-lethal interactions to target triple-negative breast cancers$116,507
K99 · FY2013 · CA · contact PI